Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Madrid
Clinical trial register · Spain

Clinical Trials in Madrid, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC
5875
Studies in scope
all four open statuses
3096
Recruiting now
open to new participants
1137
Lead sponsors
across recruiting studies
Top sites
Barcelona 56 Madrid 54 Valencia 21 Málaga 19 Santander 14
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca183 Janssen Research & Development, LLC109 Merck Sharp & Dohme LLC106 Novartis Pharmaceuticals100 Hoffmann-La Roche92 Clear sponsor filter
Site location
Barcelona56 Madrid54 Valencia21 Málaga19 Santander14
All 70 locations
Target enrolment
to

Trials with a site in Madrid

54 of 5875 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Spain
Start
Recruiting
GlaxoSmithKline
Phase 1
28
Madrid
2026-08-20
Recruiting
GlaxoSmithKline
Phase 3
800
BaracaldoVizcaya, Barcelona, Madrid, Seville, Zaragoza
2026-07-27
Recruiting
GlaxoSmithKline
Phase 2
200
Jerez de la Frontera, Badalona, Córdoba, Gijón, Madrid, Málaga, Salamanca, Vitoria-Gasteiz
2026-04-15
Recruiting
GlaxoSmithKline
Phase 1
97
Barcelona, Madrid
2026-03-23
Recruiting
GlaxoSmithKline
Phase 1
44
Barcelona, Madrid
2026-02-10
Recruiting
GlaxoSmithKline
Phase 1
83
Barcelona, Madrid, Málaga
2025-12-03
Recruiting
GlaxoSmithKline
Phase 3
450
Barcelona, Madrid, Oviedo, Seville, Valencia, Zaragoza
2025-12-03
Recruiting
GlaxoSmithKline
Phase 2
363
Barcelona, Lleida, Madrid, MErida Badajoz, Oviedo, Valencia
2025-10-30
Recruiting
GlaxoSmithKline
Phase 1/2
47
Barcelona, Madrid
2025-10-20
Recruiting
GlaxoSmithKline
Phase 3
420
Barcelona, L'Hospitalet de Llobrega, Las Palmas de Gran Canar, Madrid, Santander
2025-08-11
Active, closed
GlaxoSmithKline
Phase 2
168
A Coruña, Barcelona, Córdoba, Madrid, Santander
2025-08-06
Recruiting
GlaxoSmithKline
Phase 3
981
Pozuelo de Alarcón, Marbella, Alzira, Barcelona, Benalmádena, Ferrol, GaldakaoVizcaya, Madrid
2025-06-20
Recruiting
GlaxoSmithKline
Phase 1/2
85
Badajoz, Barcelona, Madrid, Málaga, Pozuelo de AlarcOn Madr
2025-06-12
Recruiting
GlaxoSmithKline
Phase 1/2
451
Barcelona, HebrOn, Madrid, Pamplona, Santander, Zaragoza
2025-06-11
Recruiting
GlaxoSmithKline
Phase 2
80
Barcelona, Madrid, Málaga, Ourense, PamplonaNavarra, Salamanca, Valencia
2025-06-05
Active, closed
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
NCT06521567Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma, Glioblastoma Multiforme (GBM)
DrugsCobolimab·Dostarlimab
GlaxoSmithKline
Phase 1/2
83
Barcelona, Madrid, Valencia
2025-03-06
Recruiting
GlaxoSmithKline
Phase 1/2
305
A Coruña, Barcelona, Madrid, Málaga, Valencia, Zaragoza
2025-03-04
Recruiting
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
NCT06517875Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
DrugsMomelotinib·Reblozyl·Luspatercept
GlaxoSmithKline
Phase 2
68
Badalona, Barcelona, Las Palmas, Madrid, Málaga, Valencia
2025-02-28
Recruiting
GlaxoSmithKline
Phase 2
120
Barcelona, Madrid, Oviedo, Valencia
2025-02-18
Active, closed
GlaxoSmithKline
Phase 2
307
Alcorcon Madrid, Barcelona, Benalmádena, Jerez de la Frontera, Madrid, Málaga, Santander, Seville
2025-02-10
Recruiting
GlaxoSmithKline
Phase 3
520
Badalona, Barcelona, Gijón, Madrid, Málaga, Murcia, Salamanca, Santander
2024-12-16
Active, closed
GlaxoSmithKline
Phase 1/2
14
Barcelona, Madrid, Málaga
2024-12-13
Active, closed
GlaxoSmithKline
Phase 1
86
Barcelona, Madrid
2024-12-11
Active, closed
GlaxoSmithKline
Phase 2
283
Barcelona, León, Madrid, Salamanca, Santander, Valencia
2024-11-11
Recruiting
GlaxoSmithKline
Phase 1
845
Badajoz, Barcelona, Madrid, Málaga, Valencia, Zaragoza
2024-09-30
Recruiting
GlaxoSmithKline
Phase 2
393
Barcelona, León, Madrid, Santander, Seville, Valencia, Valladolid, Vigo
2024-09-27
Active, closed
GlaxoSmithKline
Phase 2
153
Barcelona, Córdoba, Madrid
2024-09-17
Recruiting
GlaxoSmithKline
Phase 3
440
Pamplona Iruna, Barcelona, Córdoba, Granada, Madrid, Málaga, Santander, Seville
2024-09-11
Active, closed
GlaxoSmithKline
Phase 3
10,212
Santiago de Compostela, Centelles, Vic, Majadahonda, Alcorcón, Barcelona, Madrid, Valencia
2024-08-01
Recruiting
GlaxoSmithKline
Phase 3
150
Barcelona, Benalmádena, Madrid, Palma de Mallorca, Santander
2024-07-19
Recruiting
GlaxoSmithKline
Phase 1
675
Barcelona, Córdoba, Girona, Madrid, Pozuelo de AlarcOn Madr
2024-07-02
Active, closed
GlaxoSmithKline
Phase 3
88
A Coruña, Aravaca, BaracaldoVizcaya, Barcelona, Jaén, Las Palmas de Gran Canar, Madrid, Oviedo
2024-06-10
Recruiting
GlaxoSmithKline
Phase 3
864
BaracaldoVizcaya, Barcelona, Cartagena Murcia, HebrOn, Jerez de la Frontera, L'Hospitalet de Llobrega, Lugo, Madrid
2024-03-21
Active, closed
GlaxoSmithKline
Phase 2
316
Barcelona, Jaén, Madrid, Pozuelo de AlarcOn Madr, Salamanca, Santander, Valencia, Zaragoza
2023-11-14
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
DrugBelimumab
GlaxoSmithKline
Phase 2/3
300
Barcelona, Bilbao, Granada, Madrid, Seville, Valencia, VigoPontevedra
2023-09-13
Active, closed
GlaxoSmithKline
Phase 2
154
Barcelona, Granada, Madrid, Santander, Valencia
2023-04-03
Active, closed
Phase 2b Study of GSK4532990 in Adults With NASH
NCT05583344Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
DrugGSK4532990
GlaxoSmithKline
Phase 2
284
Barcelona, Madrid, Málaga, Sabadell Barcelona, Santander, Seville, Vigo
2023-01-02
Active, closed
GlaxoSmithKline
Phase 2
351
Badajoz, Badalona, Barcelona, Las Palmas de Gran Canar, Madrid, Málaga, PamplonaNavarra, Valencia
2022-10-14
Recruiting
GlaxoSmithKline
Phase 3
109
Barcelona, Granada, Madrid, Pozuelo de AlarcOn Madr, Salamanca, Valencia, Zaragoza
2022-09-06
Active, closed
GlaxoSmithKline
Phase 3
3,038
Balenyà (Barcelona), Barcelona, Centelles (Barcelona), La Roca del Vallès, Madrid, Majadahonda( Madrid, Marid, Peralada( Girona)
2022-08-10
Active, closed
GlaxoSmithKline
Phase 1
152
Barcelona, Madrid, Málaga
2022-03-22
Active, closed
GlaxoSmithKline
Phase 2
360
HebrOn, León, Madrid, Santander, Valencia, Vigo
2021-12-14
Active, closed
GlaxoSmithKline
Phase 1/2
30
Madrid, Pozuelo de AlarcOn Madr
2021-07-29
Active, closed
GlaxoSmithKline
Phase 3
40
Barcelona, Cáceres, Córdoba, Granada, Madrid, Málaga, Santiago de Compostela, Valencia
2021-06-28
Recruiting
GlaxoSmithKline
Phase 2
37
Madrid
2021-04-16
Active, closed
GlaxoSmithKline
Phase 2/3
758
A Coruña, Badalona, Barcelona, Burgos, Córdoba, Las Palmas de Gran Canar, Madrid, Málaga
2020-12-08
Active, closed
GlaxoSmithKline
Phase 3
302
Barcelona, Gijón, L'Hospitalet de Llobrega, Madrid, MOstoles Madrid, Murcia, Palma de Mallorca, PamplonaNavarra
2020-10-01
Active, closed
GlaxoSmithKline
Phase 3
242
Barcelona, Madrid, Seville, Valencia
2020-07-14
Active, closed
GlaxoSmithKline
Phase 1/2
106
Badalona, Madrid, Pozuelo de AlarcOn Madr
2020-06-08
Active, closed
GlaxoSmithKline
Phase 1
118
Badalona, Barcelona, Madrid, Málaga, PamplonaNavarra, Pozuelo de AlarcOn Madr, Santander
2019-12-18
Active, closed
GlaxoSmithKline
Phase 2
25
Barcelona, Madrid, Valencia
2019-11-28
Recruiting
GlaxoSmithKline
Phase 1/2
184
BaracaldoVizcaya, Espluges de Llobregat, HebrOn, Madrid, Seville
2019-10-25
Active, closed
GlaxoSmithKline
Phase 1/2
208
Badalona, Madrid, PamplonaNavarra, Pozuelo de AlarcOn Madr
2019-10-07
Active, closed
Extended Access of Momelotinib in Adults With Myelofibrosis
NCT03441113Neoplasms, Post-polycythemia Vera Myelofibrosis (Post-PV MF), Primary Myelofibrosis (PMF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
GlaxoSmithKline
Phase 2
237
Barcelona, Madrid, Pamplona, Zaragoza
2018-05-03
Rows per page Showing 1–54 of 54
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-spain/city/madrid

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 54 of those studies with a site in Madrid that also match the filters currently applied.

How many clinical trials are recruiting in Madrid?

28 of the 54 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 26 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Madrid), 54 studies
PhaseStudiesRecruitingShare
Phase 218733.3%
Phase 315927.8%
Phase 1/210518.5%
Phase 19616.7%
Phase 2/3213.7%

Most active sponsors

Lead sponsors with the most studies (Madrid)
Lead sponsorStudiesRecruiting
GlaxoSmithKline5428
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.